PA21
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Peritoneal Dialysis
Conditions
Peritoneal Dialysis, Hyperphosphatemia
Trial Timeline
— → —
NCT ID
NCT01852682About PA21
PA21 is a phase 3 stage product being developed by Kissei Pharmaceutical for Peritoneal Dialysis. The current trial status is completed. This product is registered under clinical trial identifier NCT01852682. Target conditions include Peritoneal Dialysis, Hyperphosphatemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01852682 | Phase 3 | Completed |
| NCT01850641 | Phase 3 | Completed |
| NCT01833494 | Phase 3 | Completed |
Competing Products
20 competing products in Peritoneal Dialysis